Fishing upstream

Anti-inflammatory biologics have transformed the treatment of autoimmune diseases, but Johnson & Johnson's Janssen Research & Development LLC unit wants to intercept the processes that lead to inflammation in the first place.

As early as next year, the pharma's immunology group plans to enter the clinic with a program that could halt inflammatory bowel disease (IBD) before inflammation can damage tissues...